BULL POINTS:
â– Vyvanse sales growing solidly
â– Impressive portfolio of human genetic therapy products
â– Potential takeover candidate
â– Relatively robust financial position
BEAR POINTS:
â– Generic competition to Adderall XR
â– Thin dividend yield
IC TIP:
Buy
at
1063p
Shire's presentation in November on its human genetic therapy (HGT) products generated plenty of hype. But the company's nearer-term performance will be dominated by its attention-deficit and hyperactivity disorder (ADHD) treatments. And there is plenty to take comfort from there.